Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccinia and Fowlpox Tyrosinase Vaccines with IL-2 in Metastatic Melanoma
NCT00054535Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of vaccinia-tyrosinase, recombinant fowlpox-tyrosinase vaccine in melanoma, sponsored by National Cancer Institute. Started Jan 2003; status: completed.
02
Drugs
vaccinia-tyrosinaserecombinant fowlpox-tyrosinase vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00054535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054535.